Clinical features of the overall study cohort and GCB and ABC subtypes of DLBCL newly defined in the current study
| . | Overall, n (%) . | GCB, n (%) . | ABC, n (%) . | GCB vs ABC, P . |
|---|---|---|---|---|
| Patients | 418 (100) | 202 (100) | 216 (100) | |
| Sex | ||||
| Male | 229 (54.8) | 110 (54.5) | 119 (55.1) | .92 |
| Female | 189 (45.2) | 92 (45.5) | 97 (44.9) | |
| Age, y | ||||
| ≤60 | 178 (42.6) | 100 (49.5) | 78 (36.1) | .0075 |
| >60 | 240 (57.4) | 102 (50.5) | 138 (63.9) | |
| Stage of disease | ||||
| I-II | 185 (46.0) | 106 (54.6) | 79 (38.0) | .0009 |
| III-IV | 217 (54.0) | 88 (45.4) | 129 (62.0) | |
| Serum LDH level | ||||
| Normal | 144 (37.0) | 80 (42.6) | 64 (31.8) | .036 |
| Elevated | 245 (63.0) | 108 (57.4) | 137 (68.2) | |
| ECOG performance status | ||||
| 0-1 | 313 (82.6) | 154 (86.0) | 159 (79.5) | .10 |
| ≥2 | 66 (17.4) | 25 (14.0) | 41 (20.5) | |
| No. of extranodal sites involved | ||||
| 0-1 | 295 (74.3) | 145 (76.3) | 150 (72.5) | .42 |
| ≥2 | 102 (25.7) | 45 (23.7) | 57 (27.5) | |
| IPI risk group | ||||
| 0-2 | 246 (60.9) | 133 (68.9) | 113 (53.6) | .0022 |
| 3-5 | 158 (39.1) | 60 (31.1) | 98 (46.4) | |
| B-symptoms | ||||
| Absence | 267 (66.8) | 141 (73.8) | 126 (60.3) | .0042 |
| Presence | 133 (33.3) | 50 (26.2) | 83 (39.7) | |
| Tumor size, cm | ||||
| <5 | 189 (58.9) | 91 (59.5) | 98 (58.3) | .91 |
| ≥5 | 132 (41.1) | 62 (40.5) | 70 (41.7) | |
| COO by Affymetrix GEP | ||||
| GCB | 172 (47.0) | 149 (86.1) | 23 (11.9) | <.0001 |
| ABC | 160 (43.7) | 8 (4.6) | 152 (78.9) | |
| UC | 34 (9.3) | 16 (8.7) | 18 (9.3) | |
| COO by GEP and IHC | ||||
| GCB | 209 (50.9) | 180 (90.5) | 29 (13.7) | <.0001 |
| ABC | 202 (49.1) | 19 (9.5) | 183 (86.3) | |
| . | Overall, n (%) . | GCB, n (%) . | ABC, n (%) . | GCB vs ABC, P . |
|---|---|---|---|---|
| Patients | 418 (100) | 202 (100) | 216 (100) | |
| Sex | ||||
| Male | 229 (54.8) | 110 (54.5) | 119 (55.1) | .92 |
| Female | 189 (45.2) | 92 (45.5) | 97 (44.9) | |
| Age, y | ||||
| ≤60 | 178 (42.6) | 100 (49.5) | 78 (36.1) | .0075 |
| >60 | 240 (57.4) | 102 (50.5) | 138 (63.9) | |
| Stage of disease | ||||
| I-II | 185 (46.0) | 106 (54.6) | 79 (38.0) | .0009 |
| III-IV | 217 (54.0) | 88 (45.4) | 129 (62.0) | |
| Serum LDH level | ||||
| Normal | 144 (37.0) | 80 (42.6) | 64 (31.8) | .036 |
| Elevated | 245 (63.0) | 108 (57.4) | 137 (68.2) | |
| ECOG performance status | ||||
| 0-1 | 313 (82.6) | 154 (86.0) | 159 (79.5) | .10 |
| ≥2 | 66 (17.4) | 25 (14.0) | 41 (20.5) | |
| No. of extranodal sites involved | ||||
| 0-1 | 295 (74.3) | 145 (76.3) | 150 (72.5) | .42 |
| ≥2 | 102 (25.7) | 45 (23.7) | 57 (27.5) | |
| IPI risk group | ||||
| 0-2 | 246 (60.9) | 133 (68.9) | 113 (53.6) | .0022 |
| 3-5 | 158 (39.1) | 60 (31.1) | 98 (46.4) | |
| B-symptoms | ||||
| Absence | 267 (66.8) | 141 (73.8) | 126 (60.3) | .0042 |
| Presence | 133 (33.3) | 50 (26.2) | 83 (39.7) | |
| Tumor size, cm | ||||
| <5 | 189 (58.9) | 91 (59.5) | 98 (58.3) | .91 |
| ≥5 | 132 (41.1) | 62 (40.5) | 70 (41.7) | |
| COO by Affymetrix GEP | ||||
| GCB | 172 (47.0) | 149 (86.1) | 23 (11.9) | <.0001 |
| ABC | 160 (43.7) | 8 (4.6) | 152 (78.9) | |
| UC | 34 (9.3) | 16 (8.7) | 18 (9.3) | |
| COO by GEP and IHC | ||||
| GCB | 209 (50.9) | 180 (90.5) | 29 (13.7) | <.0001 |
| ABC | 202 (49.1) | 19 (9.5) | 183 (86.3) | |
Significant P values are in boldface.
ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; IPI, International Prognostic Index.